ZEN Graphene Solutions Ltd - Asset Resilience Ratio
ZEN Graphene Solutions Ltd (ZEN) has an Asset Resilience Ratio of 4.79% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ZEN total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how ZEN Graphene Solutions Ltd's Asset Resilience Ratio has changed over time. See ZEN total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ZEN Graphene Solutions Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ZEN market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$1.00 Million | 4.79% |
| Total Liquid Assets | CA$1.00 Million | 4.79% |
Asset Resilience Insights
- Limited Liquidity: ZEN Graphene Solutions Ltd maintains only 4.79% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ZEN Graphene Solutions Ltd Industry Peers by Asset Resilience Ratio
Compare ZEN Graphene Solutions Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.08% |
|
Vizionfocus Inc.
TW:4771 |
Medical Instruments & Supplies | 5.07% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.23% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 43.09% |
Annual Asset Resilience Ratio for ZEN Graphene Solutions Ltd (2010–2024)
The table below shows the annual Asset Resilience Ratio data for ZEN Graphene Solutions Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-03-31 | 13.28% | CA$3.00 Million ≈ $2.17 Million |
CA$22.59 Million ≈ $16.34 Million |
+12.76pp |
| 2022-03-31 | 0.53% | CA$200.00K ≈ $144.68K |
CA$37.98 Million ≈ $27.48 Million |
-- |
| 2018-03-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$22.22 Million ≈ $16.08 Million |
-- |
| 2017-03-31 | 2.69% | CA$613.28K ≈ $443.64K |
CA$22.80 Million ≈ $16.49 Million |
+1.47pp |
| 2016-03-31 | 1.22% | CA$262.86K ≈ $190.15K |
CA$21.54 Million ≈ $15.59 Million |
+0.07pp |
| 2015-03-31 | 1.15% | CA$237.30K ≈ $171.66K |
CA$20.60 Million ≈ $14.90 Million |
-4.97pp |
| 2014-03-31 | 6.12% | CA$1.30 Million ≈ $942.70K |
CA$21.29 Million ≈ $15.40 Million |
-1.49pp |
| 2013-03-31 | 7.61% | CA$1.29 Million ≈ $933.10K |
CA$16.95 Million ≈ $12.26 Million |
-15.08pp |
| 2012-03-31 | 22.69% | CA$2.56 Million ≈ $1.85 Million |
CA$11.26 Million ≈ $8.15 Million |
-47.65pp |
| 2011-03-31 | 70.34% | CA$8.55 Million ≈ $6.18 Million |
CA$12.15 Million ≈ $8.79 Million |
+57.83pp |
| 2010-03-31 | 12.52% | CA$400.18K ≈ $289.49K |
CA$3.20 Million ≈ $2.31 Million |
-- |
About ZEN Graphene Solutions Ltd
Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coatings under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It also… Read more